These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 12036194

  • 1. Carvedilol does not modulate moderate exercise-induced hyperkalemia in hemodialysis patients.
    Nowicki M, Szewczyk-Seifert G, Klimek D, Kokot F.
    Clin Nephrol; 2002 May; 57(5):352-8. PubMed ID: 12036194
    [Abstract] [Full Text] [Related]

  • 2. Influence of the alpha-1-adrenergic receptor blocker doxazosin on exercise-induced hyperkalemia in hemodialysis patients.
    Nowicki M, Waluś T, Kokot F.
    Kidney Blood Press Res; 2002 May; 25(1):55-60. PubMed ID: 11834878
    [Abstract] [Full Text] [Related]

  • 3. Stereoselective effects of (R)- and (S)-carvedilol in humans.
    Stoschitzky K, Koshucharova G, Lercher P, Maier R, Sakotnik A, Klein W, Liebmann PM, Lindner W.
    Chirality; 2001 Jul; 13(7):342-6. PubMed ID: 11400186
    [Abstract] [Full Text] [Related]

  • 4. Nonselective Beta-adrenergic blockade augments fasting hyperkalemia in hemodialysis patients.
    Nowicki M, Miszczak-Kuban J.
    Nephron; 2002 Jun; 91(2):222-7. PubMed ID: 12053057
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans.
    Herman RB, Jesudason PJ, Mustafa AM, Husain R, Choy AM, Lang CC.
    Br J Clin Pharmacol; 2003 Feb; 55(2):134-8. PubMed ID: 12580984
    [Abstract] [Full Text] [Related]

  • 6. Nonselective beta-adrenergic blockade with carvedilol does not hinder the benefits of exercise training in patients with congestive heart failure.
    Demopoulos L, Yeh M, Gentilucci M, Testa M, Bijou R, Katz SD, Mancini D, Jones M, LeJemtel TH.
    Circulation; 1997 Apr 01; 95(7):1764-7. PubMed ID: 9107160
    [Abstract] [Full Text] [Related]

  • 7. Carvedilol-induced hyperkalemia in a patient with chronic kidney disease.
    Hahn L, Hahn M.
    J Pharm Pract; 2015 Feb 01; 28(1):107-11. PubMed ID: 25715086
    [Abstract] [Full Text] [Related]

  • 8. Differing beta-blocking effects of carvedilol and metoprolol.
    Stoschitzky K, Koshucharova G, Zweiker R, Maier R, Watzinger N, Fruhwald FM, Klein W.
    Eur J Heart Fail; 2001 Jun 01; 3(3):343-9. PubMed ID: 11378006
    [Abstract] [Full Text] [Related]

  • 9. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris.
    Lahiri A, Rodrigues EA, Al-Khawaja I, Raftery EB.
    Am J Cardiol; 1987 Apr 01; 59(8):769-74. PubMed ID: 2881480
    [Abstract] [Full Text] [Related]

  • 10. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A, Heidland A, Pangerl A, Meyer-Sabellek W, Schaefer RM.
    Clin Nephrol; 1995 Jan 01; 43(1):47-52. PubMed ID: 7697935
    [Abstract] [Full Text] [Related]

  • 11. Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.
    Hryniewicz K, Androne AS, Hudaihed A, Katz SD.
    Circulation; 2003 Aug 26; 108(8):971-6. PubMed ID: 12912816
    [Abstract] [Full Text] [Related]

  • 12. Alpha 1-blocking properties of carvedilol during acute and chronic administration.
    Giannattasio C, Cattaneo BM, Seravalle G, Carugo S, Mangoni AA, Grassi G, Zanchetti A, Mancia G.
    J Cardiovasc Pharmacol; 1992 Aug 26; 19 Suppl 1():S18-22. PubMed ID: 1378144
    [Abstract] [Full Text] [Related]

  • 13. Characteristic effects of alpha1-beta1,2-adrenergic blocking agent, carvedilol, on [Ca2+]i in ventricular myocytes compared with those of timolol and atenolol.
    Yao A, Kohmoto O, Oyama T, Sugishita Y, Shimizu T, Harada K, Matsui H, Komuro I, Nagai R, Matsuo H, Serizawa T, Maruyama T, Takahashi T.
    Circ J; 2003 Jan 26; 67(1):83-90. PubMed ID: 12520158
    [Abstract] [Full Text] [Related]

  • 14. Blood pressure lowering efficacy of dual alpha and beta blockers for primary hypertension.
    Wong GW, Laugerotte A, Wright JM.
    Cochrane Database Syst Rev; 2015 Aug 26; 2015(8):CD007449. PubMed ID: 26306578
    [Abstract] [Full Text] [Related]

  • 15. Carvedilol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.
    Dunn CJ, Lea AP, Wagstaff AJ.
    Drugs; 1997 Jul 26; 54(1):161-85. PubMed ID: 9211087
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular and renal effects of carvedilol in dogs with heart failure.
    Uechi M, Sasaki T, Ueno K, Yamamoto T, Ishikawa Y.
    J Vet Med Sci; 2002 Jun 26; 64(6):469-75. PubMed ID: 12130829
    [Abstract] [Full Text] [Related]

  • 17. Vasodilatory effects of carvedilol and pindolol.
    Sundberg S, Tiihonen K, Gordin A.
    J Cardiovasc Pharmacol; 1987 Jun 26; 10 Suppl 11():S76-80. PubMed ID: 2454373
    [Abstract] [Full Text] [Related]

  • 18. Carvedilol.
    Frishman WH.
    N Engl J Med; 1998 Dec 10; 339(24):1759-65. PubMed ID: 9845712
    [No Abstract] [Full Text] [Related]

  • 19. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol.
    Lindenfeld J, Lowes BD, Bristow MR.
    Ann Pharmacother; 1999 Dec 10; 33(12):1266-9. PubMed ID: 10630826
    [Abstract] [Full Text] [Related]

  • 20. Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects.
    Billeh R, Hirsh D, Barker C, Jorgensen B, Jeger R, Ramanathan K, Tseng CH, Hudaihed A, Haas F, Jorde UP.
    Congest Heart Fail; 2006 Dec 10; 12(5):254-7. PubMed ID: 17033273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.